Sun Pharmaceutical Industries announced Monday that the FDA has approved the ANDA for sugammadex sodium, expanding a strategic market opportunity within the rapidly growing reversal agent segment and strengthening its position in critical care pharmacotherapy. This approval gives Sun broader access to this high-demand, high-value IV therapy, positioning the company to capture a significant share of the glycine receptor antagonist market.